Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

Pembrolizumab in MSI-H CRC Tumors

July 13th 2017

Role of Trifluridine/Tipiracil in CRC

July 13th 2017

Patient Selection for Regorafenib in CRC

July 13th 2017

Sequencing Considerations in MSS CRC Tumors

July 13th 2017

Exploring Second-Line Therapeutic Options in mCRC

July 13th 2017

Global Perspectives and Initial Decisions in mCRC

July 13th 2017

IDEA Trial: 3 vs 6 Months of Adjuvant Therapy in CRC

July 13th 2017

Exploring Global Variations in Molecular Profiling

July 13th 2017

Maintenance and Second-Line Decisions in mCRC

July 13th 2017

Frontline Decisions in RAS Wild-Type Left-Sided mCRC

July 13th 2017

Nuances in Antibody Selection: Left Vs Right-Sided mCRC

July 13th 2017

Prognostic/Predictive Value of Tumor-Sidedness in CRC

July 13th 2017

Colorectal Cancer Prevention and Screening: An Update

July 13th 2017

Early- Versus Late-Onset Colorectal Cancer

July 13th 2017

Expert Discusses State of CAR T-Cell Therapy in ALL

July 13th 2017

Bajil J. Shah, MD, discusses the significant impact CAR T-cell therapy can have on the treatment landscape for patients with acute lymphoblastic leukemia.

ODAC Unanimously Recommends Approval of Tisagenlecleucel for Pediatric ALL

July 12th 2017

Oncologic Drugs Advisory Committee voted 10-0 today to recommend approval of a biologics license application for tisagenlecleucel (CTL019) for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia.

FDA Grants Full Approval to Blinatumomab for B-cell Precursor ALL

July 12th 2017

The FDA has granted a full approval to blinatumomab (Blincyto) as a treatment for adults and children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, regardless of Philadelphia chromosome status.

ODAC Recommends Approval of Gemtuzumab Ozogamicin for Newly-Diagnosed AML

July 11th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 6-1 in favor of approving gemtuzumab ozogamicin (Mylotarg) in combination with daunorubicin and cytarabine for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia.

Genentech Survey: Many Practices Unprepared for USP

July 10th 2017

In 2016, just a quarter of oncology practices considered themselves prepared for upcoming US Pharmacopeia (USP) standards on hazardous drug management, according to the 2017 Genentech Oncology Trend Report.

Time to Focus on Succession Planning as Retirements Loom

July 10th 2017

Joliet Oncology-Hematology decided to create new governance and compensation structures and eventually elected a new president.